Posts by Andrew S. Allegretti, MD, MSc
-
Novel Anticoagulation Protocol to Decrease Hemofilter Clotting in COVID-19 Patients
In a pilot study, Massachusetts General Hospital researchers found that dosing systemic heparin according to anti–factor Xa levels resulted in improved hemofilter life in critically ill COVID-19 patients undergoing continuous venovenous hemofiltration.
Biography
Andrew Allegretti, MD, MSc, is director of Critical Care Nephrology in the Division of Nephrology at Massachusetts General Hospital and Assistant Professor of Medicine at Harvard Medical School. He received his undergraduate and medical degree from Brown University and has a Master of Science in Epidemiology from the Harvard School of Public Health. He completed residency training in Internal Medicine at MGH, followed by subspecialty training in Nephrology in the Brigham and Women’s Hospital/Massachusetts General Hospital joint fellowship. He takes care of all patients with chronic kidney disease. He does clinical and translational research in kidney disease caused by liver failure, sometimes called hepatorenal syndrome.
